The year 2022 saw some negative press about prenatal circulating DNA screening tests, from New York Times on January 1, from ProPublica on December 6.
In April ACLA issued a short rebuttal linked to a more detailed 3 page PDF on NIPS.
Now on December 12, ACLA specifically addressed ProPublica concerns and labeled it "misleading information" that "fails to provide an up-to-date picture." Find the new ACLA press release here.
The December ACLA comment makes 6 points:
- NIPS is a screening test (it is not a diagnostic test, it is used to trigger other tests).
- NIPS is a significant advance over the prior status quo.
- Use of testing is voluntary.
- Only health care providers can order NIPS.
- Laboratories that offer NIPS have high standards.
- ACLA is actively engaged in regulatory reform discussions on Capitol Hill.
__
It's a jump, but for comparison, you might see new Alz. Assoc. letters re evidence & validity to CMS, here.
